BioSante Gains on Approval of Testosterone Gel: Chicago Mover
This article is for subscribers only.
BioSante Pharmaceuticals Inc. rose 27 percent after the testosterone replacement therapy it developed for men won U.S. regulatory approval.
BioSante gained 21 cents to close at 97 cents in New York. The U.S. Food and Drug Administration announced yesterday that it approved the transdermal gel, Bio-T-Gel. The product will be marketed by Teva Pharmaceutical Industries Ltd. of Petach Tikva, Israel, for men with low testosterone levels, a condition known as hypogonadism.